FHI Clinical Partners With IDRI to Provide Full-Service CRO Capabilities for COVID-19 Trials

Published on: 

Applied Clinical Trials

FHI Clinical Inc. has announced it has partnered with Infectious Disease Research Institute (IDRI) to provide full-service contract research organization capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19. IDRI recently received funding from Celularity launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment as a potential treatment option against the novel coronavirus.

For more information, click here.